Vaxcyte Inc annual free cash flow for fiscal TTM was -$1.2 billion, a decrease of 81.5% from -$669 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Free Cash Flow (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | ($1.2B) | ($669M) | ($475M) | ($365M) | ($176M) | ($128M) | ($48M) | ($48M) | ($32M) | $0M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Free Cash Flow (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | ($237M) | ($295M) | ($230M) | ($155M) | ($141M) | ($193M) | ($141M) | ($99M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More PCVX metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Shares Outstanding
All PCVX financial statements → Interactive PCVX charts →
About TickerBase · Data methodology & sources · Privacy · Terms